organization · Reporting owner

Abingworth LLP

Disclosed activity across 9 companies

Tapewire entity: 94434
SEC CIK: 0001397144

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Sierra Oncology, Inc.SRRA · Entity 125698	10% owner	January 28, 2022	February 01, 2022
Vaxcyte, Inc.PCVX · Entity 1164	10% owner	June 11, 2020	June 16, 2020
Vera Therapeutics, Inc.VERA · Entity 4358	10% owner	August 17, 2022	August 19, 2022
eFFECTOR Therapeutics, Inc.EFTR · Entity 89916	10% owner	October 06, 2021	December 17, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Sierra Oncology, Inc.

Report date January 28, 2022 · Filed February 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectSee footnote	1,314,127	Last balance in matching sequence After 2022-01-31 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2022-01-28 · Other · Acquired 287,471 · Balance 1,164,127 F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2022-01-31 · Purchase · Acquired 150,000 · Balance 1,314,127 F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Series B Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20	IndirectSee footnote	0	Reported balance After 2022-01-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-01-28 · Other · Disposed 287,471 · Balance 0 F2: Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib. F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib.

Vaxcyte, Inc.

Report date June 11, 2020 · Filed June 16, 2020 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2030-06-10	IndirectSee Footnotes	40,000	Reported balance After 2020-06-11 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2020-06-11 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. F2: These options (the "Option") were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP. F3: ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: 1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter.

F2: These options (the "Option") were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP.

F3: ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Vera Therapeutics, Inc.

Report date August 17, 2022 · Filed August 19, 2022

Jointly reported with Carlyle Group Inc., Abingworth Bioventures 8 LP, Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L.C., TC Group, LLC, Carlyle Investment Management LLC, Carlyle Genesis UK LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnotes	2,960,231	Last balance in matching sequence After 2022-08-17 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2022-08-17 · Exercise / conversion · Acquired 9,925 · Balance 2,970,156 F1: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. Row 2 · 2022-08-17 · Sale · Disposed 3,281 · Balance 2,966,875 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $19.995. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. Row 3 · 2022-08-17 · Sale · Disposed 6,472 · Balance 2,960,403 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. Row 4 · 2022-08-17 · Sale · Disposed 172 · Balance 2,960,231 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.025 to $21.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2031-05-12	IndirectSee footnotes	0	Reported balance After 2022-08-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-08-17 · Exercise / conversion · Disposed 9,925 · Balance 0 F6: The stock option is fully vested and exercisable. F1: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. F7: Under an agreement between Kurt von Emster and Abingworth LLP, Mr. von Emster is deemed to hold the stock option and any shares of Class A Common Stock issuable upon exercise of the stock option for the benefit of ABV 8, and must exercise the stock option solely upon the direction of Abingworth LLP.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8.

F2: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $19.995. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.025 to $21.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The stock option is fully vested and exercisable.

F7: Under an agreement between Kurt von Emster and Abingworth LLP, Mr. von Emster is deemed to hold the stock option and any shares of Class A Common Stock issuable upon exercise of the stock option for the benefit of ABV 8, and must exercise the stock option solely upon the direction of Abingworth LLP.

eFFECTOR Therapeutics, Inc.

Report date October 06, 2021 · Filed December 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.36 · Expires 2031-10-05	IndirectSee Footnotes	40,000	Reported balance After 2021-10-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-10-06 · Grant · Acquired 40,000 · Balance 40,000 F2: The option (the "Option") was granted to Brian Gallagher ("Gallagher"), a director of the Issuer and a member of the investment committee of ABV VI (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VI. The Option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Gallagher's continued service with the Issuer through each vesting date. Under an agreement between Gallagher and the Reporting Person, Gallagher is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of the Reporting Person. F1: Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VI, LP ("ABV VI"). Abingworth General Partner VI LLP serves as the general partner of Abingworth GP. ABV VI (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VI. F3: ABV VI may be deemed the indirect beneficial owner of the Option, and Gallagher may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. Each of ABV VI, Abingworth GP, Abingworth General Partner VI LLP, Gallagher, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VI, LP ("ABV VI"). Abingworth General Partner VI LLP serves as the general partner of Abingworth GP. ABV VI (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VI.

F2: The option (the "Option") was granted to Brian Gallagher ("Gallagher"), a director of the Issuer and a member of the investment committee of ABV VI (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VI. The Option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Gallagher's continued service with the Issuer through each vesting date. Under an agreement between Gallagher and the Reporting Person, Gallagher is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of the Reporting Person.

F3: ABV VI may be deemed the indirect beneficial owner of the Option, and Gallagher may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. Each of ABV VI, Abingworth GP, Abingworth General Partner VI LLP, Gallagher, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Jasper Therapeutics, Inc.

Report date February 08, 2024 · Filed February 12, 2024

Jointly reported with Carlyle Group Inc., Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L.C., TC Group, LLC, Carlyle Investment Management LLC, Carlyle Genesis UK LLC, Abingworth Bioventures VII LP

Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Voting Common StockSEC Table I · non-derivative	IndirectSee footnotes	1,066,189	Reported balance After 2024-02-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-02-08 · Purchase · Acquired 190,000 · Balance 1,066,189 F1: The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024. F2: Reflects securities held of record by Abingworth Bioventures VII LP ("ABV VII"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. F3: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024.

F2: Reflects securities held of record by Abingworth Bioventures VII LP ("ABV VII"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII.

F3: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any.

Personalis, Inc.

Report date October 20, 2020 · Filed October 21, 2020

Section 16 reporting ended · disclosed 2020-10-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.0001 par value per shareSEC Table I · non-derivative	IndirectSee Footnote	3,753,340	Reported balance After 2020-10-20 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-10-20 · Sale · Disposed 130,486 · Balance 3,753,340 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $29.07 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $29.07 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Protara Therapeutics, Inc.

Report date November 12, 2019 · Filed November 14, 2019

Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectSee Footnote	2,144,517	Reported balance After 2019-11-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-11-12 · Conversion · Acquired 126,645 · Balance 2,144,517 F1: The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.99	IndirectSee Footnote	2,400	Reported balance After 2019-11-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-12 · Conversion · Disposed 126 · Balance 2,400 F2: The Series A convertible preferred stock (the "Series A Stock") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. F3: The Series A Stock has no expiration date. F4: The Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding. F1: The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: The Series A convertible preferred stock (the "Series A Stock") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949.

F3: The Series A Stock has no expiration date.

F4: The Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding.

SOLENO THERAPEUTICS INC

Report date September 28, 2023 · Filed October 02, 2023

Section 16 reporting ended · disclosed 2023-10-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	1,531,436	Reported balance After 2023-09-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-09-28 · Conversion · Acquired 329,930 · Balance 1,531,436 F1: On September 28, 2023, Abingworth Bioventures VII LP ("ABV VII") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the "Prefunded Warrants"). F2: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities"). F3: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein.
Tranche A WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $1.75	IndirectSee Footnotes	0	Reported balance After 2023-09-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-28 · Conversion · Disposed 1,092,056 · Balance 0 F1: On September 28, 2023, Abingworth Bioventures VII LP ("ABV VII") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the "Prefunded Warrants"). F4: The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result ABV VII obtaining greater than 9.99% of the Issuer's voting securities. F2: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities"). F3: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein.
Prefunded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.01	IndirectSee Footnotes	762,126	Reported balance After 2023-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-28 · Conversion · Acquired 762,126 · Balance 762,126 F1: On September 28, 2023, Abingworth Bioventures VII LP ("ABV VII") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the "Prefunded Warrants"). F5: The Prefunded Warrants are immediately exercisable and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in ABV VII beneficially owning greater than 9.99% of the Issuer's voting securities. F2: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities"). F3: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On September 28, 2023, Abingworth Bioventures VII LP ("ABV VII") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the "Prefunded Warrants").

F2: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities").

F3: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein.

F4: The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result ABV VII obtaining greater than 9.99% of the Issuer's voting securities.

F5: The Prefunded Warrants are immediately exercisable and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in ABV VII beneficially owning greater than 9.99% of the Issuer's voting securities.

Sientra, Inc.

Report date May 07, 2018 · Filed May 09, 2018

Section 16 reporting ended · disclosed 2018-05-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Notes	2,480,494	Reported balance After 2018-05-07 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-05-07 · Purchase · Acquired 281,482 · Balance 2,480,494 F1: Consists of (i) 1,240,247 shares held of record by Abingworth Bioventures V LP ("ABV V"), and (ii) 1,240,247 shares held of record by Abingworth Bioventures V Co-Invest Growth Equity Fund LP ("AGE"). ABV V and AGE are collectively referred to as the "Abingworth Funds." The investment manager of the Abingworth Funds is Abingworth LLP ("Abingworth"). Abingworth Bioventures V GP LP ("Abingworth GP"), a Scottish limited partnership, serves as the general partner of each of the Abingworth Funds. Abingworth General Partner V LLP, a Scottish limited liability partnership, serves as the general partner of Abingworth GP. Abingworth GP (acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth all investment and dispositive power over the shares held by the Abingworth Funds. The reporting person holds the reported securities indirectly through the Abingworth Funds. F2: The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, the Abingworth Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of (i) 1,240,247 shares held of record by Abingworth Bioventures V LP ("ABV V"), and (ii) 1,240,247 shares held of record by Abingworth Bioventures V Co-Invest Growth Equity Fund LP ("AGE"). ABV V and AGE are collectively referred to as the "Abingworth Funds." The investment manager of the Abingworth Funds is Abingworth LLP ("Abingworth"). Abingworth Bioventures V GP LP ("Abingworth GP"), a Scottish limited partnership, serves as the general partner of each of the Abingworth Funds. Abingworth General Partner V LLP, a Scottish limited liability partnership, serves as the general partner of Abingworth GP. Abingworth GP (acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth all investment and dispositive power over the shares held by the Abingworth Funds. The reporting person holds the reported securities indirectly through the Abingworth Funds.

F2: The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, the Abingworth Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 08, 2024 Filed Feb 12, 2024 18:23 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	190,000	$12.95	$2,460,500.00	Disclosure SEC source: 0000950170-24-014017 · ownership.xml · nonDerivative · entry 1 Carlyle Group Inc. · CIK 0001527166 · Former 10% Owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures VII LP · CIK 0001688313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,066,189 F1 · balance_after: The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024. F2 · ownership.nature: Reflects securities held of record by Abingworth Bioventures VII LP ("ABV VII"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. F3 · ownership.nature: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any. Read SEC document
September 28, 2023 Filed Oct 2, 2023 19:54 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	ConversionPrefunded Warrants · Derivative	762,126	$1.75 Strike: $0.01	$1,333,720.50	Disclosure SEC source: 0000899243-23-019658 · doc4.xml · derivative · entry 3 Carlyle Group Inc. · CIK 0001527166 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures VII LP · CIK 0001688313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 762,126 Underlying: Common Stock · 762,126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 28, 2023, Abingworth Bioventures VII LP ("ABV VII") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the "Prefunded Warrants"). F5 · derivative.exercise_date: The Prefunded Warrants are immediately exercisable and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in ABV VII beneficially owning greater than 9.99% of the Issuer's voting securities. F5 · derivative.expiration_date: The Prefunded Warrants are immediately exercisable and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in ABV VII beneficially owning greater than 9.99% of the Issuer's voting securities. F2 · ownership.nature: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities"). F3 · ownership.nature: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document
September 28, 2023 Filed Oct 2, 2023 19:54 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	ConversionTranche A Warrants · Derivative	1,092,056	$0.00 Strike: $1.75	$0.00	Disclosure SEC source: 0000899243-23-019658 · doc4.xml · derivative · entry 2 Carlyle Group Inc. · CIK 0001527166 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures VII LP · CIK 0001688313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,092,056 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 28, 2023, Abingworth Bioventures VII LP ("ABV VII") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the "Prefunded Warrants"). F4 · derivative.exercise_date: The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result ABV VII obtaining greater than 9.99% of the Issuer's voting securities. F4 · derivative.expiration_date: The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result ABV VII obtaining greater than 9.99% of the Issuer's voting securities. F2 · ownership.nature: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities"). F3 · ownership.nature: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document
September 28, 2023 Filed Oct 2, 2023 19:54 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	ConversionCommon Stock	329,930	$1.75	$577,377.50	Disclosure SEC source: 0000899243-23-019658 · doc4.xml · nonDerivative · entry 1 Carlyle Group Inc. · CIK 0001527166 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures VII LP · CIK 0001688313 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,531,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 28, 2023, Abingworth Bioventures VII LP ("ABV VII") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the "Prefunded Warrants"). F2 · ownership.nature: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities"). F3 · ownership.nature: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document
May 08, 2023 Filed May 10, 2023 16:30 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseTranche B Warrants · Derivative	1,778,000	$0.44 Strike: $2.50	$786,765.00	Disclosure SEC source: 0000899243-23-012501 · doc4.xml · derivative · entry 2 Carlyle Group Inc. · CIK 0001527166 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,778,000 Underlying: Common Stock · 1,778,000 shares Expires not disclosed F4 · derivative.exercise_date: The Tranche B Warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance and 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS. However, the Tranche B Warrants contain provisions preventing the Tranche B Warrants from being exercised if such exercise would result in ABV VII obtaining greater than 9.99% of the Issuer's voting securities. F4 · derivative.expiration_date: The Tranche B Warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance and 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS. However, the Tranche B Warrants contain provisions preventing the Tranche B Warrants from being exercised if such exercise would result in ABV VII obtaining greater than 9.99% of the Issuer's voting securities. F2 · ownership.nature: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities"). F3 · ownership.nature: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document
May 08, 2023 Filed May 10, 2023 16:30 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseTranche A Warrants · Derivative	1,092,056	$0.44 Strike: $1.75	$483,234.78	Disclosure SEC source: 0000899243-23-012501 · doc4.xml · derivative · entry 1 Carlyle Group Inc. · CIK 0001527166 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,092,056 Underlying: Common Stock · 1,092,056 shares Expires not disclosed F1 · derivative.exercise_date: The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result Abingworth Bioventures VII LP ("ABV VII") obtaining greater than 9.99% of the Issuer's voting securities. F1 · derivative.expiration_date: The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result Abingworth Bioventures VII LP ("ABV VII") obtaining greater than 9.99% of the Issuer's voting securities. F2 · ownership.nature: Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities"). F3 · ownership.nature: Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document
January 27, 2023 Filed Jan 31, 2023 17:24 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	3,133,333	$1.50	$4,699,999.50	Disclosure SEC source: 0000899243-23-003059 · doc4.xml · nonDerivative · entry 1 Carlyle Group Inc. · CIK 0001527166 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 8,761,891 F1 · ownership.nature: Reflects securities held of record by Abingworth Bioventures VII LP ("ABV VII"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. F2 · ownership.nature: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any. Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:39 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	Exercise / conversionStock Option (right to buy) · Derivative	9,925	$0.00 Strike: $11.00	$0.00	Disclosure SEC source: 0000899243-22-029282 · doc4.xml · derivative · entry 5 Carlyle Group Inc. · CIK 0001527166 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures 8 LP · CIK 0001811412 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Class A Common Stock · 9,925 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. F1 · ownership.nature: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2 · ownership.nature: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. F7 · ownership.nature: Under an agreement between Kurt von Emster and Abingworth LLP, Mr. von Emster is deemed to hold the stock option and any shares of Class A Common Stock issuable upon exercise of the stock option for the benefit of ABV 8, and must exercise the stock option solely upon the direction of Abingworth LLP. Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:39 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	SaleClass A Common Stock	172	$21.07	$3,624.87	Disclosure SEC source: 0000899243-22-029282 · doc4.xml · nonDerivative · entry 4 Carlyle Group Inc. · CIK 0001527166 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures 8 LP · CIK 0001811412 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,960,231 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.025 to $21.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2 · ownership.nature: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:39 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	SaleClass A Common Stock	6,472	$20.42	$132,158.89	Disclosure SEC source: 0000899243-22-029282 · doc4.xml · nonDerivative · entry 3 Carlyle Group Inc. · CIK 0001527166 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures 8 LP · CIK 0001811412 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,960,403 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2 · ownership.nature: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:39 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	SaleClass A Common Stock	3,281	$19.88	$65,242.36	Disclosure SEC source: 0000899243-22-029282 · doc4.xml · nonDerivative · entry 2 Carlyle Group Inc. · CIK 0001527166 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures 8 LP · CIK 0001811412 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,966,875 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $19.995. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2 · ownership.nature: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:39 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	Exercise / conversionClass A Common Stock	9,925	$11.00	$109,175.00	Disclosure SEC source: 0000899243-22-029282 · doc4.xml · nonDerivative · entry 1 Carlyle Group Inc. · CIK 0001527166 · 10% owner Abingworth LLP · CIK 0001397144 · 10% owner Abingworth Bioventures 8 LP · CIK 0001811412 · 10% owner Carlyle Holdings I GP Inc. · CIK 0001548626 · 10% owner Carlyle Holdings I GP Sub L.L.C. · CIK 0001548627 · 10% owner Carlyle Holdings I L.P. · CIK 0001548628 · 10% owner CG Subsidiary Holdings L.L.C. · CIK 0001790577 · 10% owner TC Group, LLC · CIK 0000933790 · 10% owner Carlyle Investment Management LLC · CIK 0001354120 · 10% owner Carlyle Genesis UK LLC · CIK 0001941860 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,970,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8. F2 · ownership.nature: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities. Read SEC document
March 29, 2022 Filed Mar 31, 2022 21:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseWarrant (right to buy) · Derivative	7,720,000	Not disclosed Strike: $0.30	Not disclosed	Disclosure SEC source: 0000905718-22-000523 · solenoth_fm4dec212018.xml · derivative · entry 7 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 7,720,000 Underlying: Common Stock · 7,720,000 shares Expires 2027-03-29 F3 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. F1 · ownership.nature: Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII. F2 · ownership.nature: The securities of Soleno Therapeutics, Inc. (the "Issuer") are held by ABV VII. The Reporting Person holds the reported securities indirectly through ABV VII. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
March 29, 2022 Filed Mar 31, 2022 21:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseCommon Stock	7,720,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000905718-22-000523 · solenoth_fm4dec212018.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 18,022,602 F3 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. F1 · ownership.nature: Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII. F2 · ownership.nature: The securities of Soleno Therapeutics, Inc. (the "Issuer") are held by ABV VII. The Reporting Person holds the reported securities indirectly through ABV VII. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
March 21, 2022 Filed Mar 23, 2022 21:30 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	GrantStock Option (right to buy) · Derivative	78,045	$0.00 Strike: $3.54	$0.00	Disclosure SEC source: 0000905718-22-000484 · jasper_fm4mar212022.xml · derivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 78,045 Underlying: Voting Common Stock · 78,045 shares Expires 2032-03-21 F2 · derivative.exercise_date: The option (the "Option") was granted to Kurt von Emster, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. The Option will vest in equal annual installments over three years, commencing on December 7, 2022, subject to the Mr. von Emster's continued service with the Issuer through each vesting date. Under an agreement between Mr. von Emster and the Reporting Person, Mr. von Emster is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of the Reporting Person. F1 · ownership.nature: Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII. F2 · ownership.nature: The option (the "Option") was granted to Kurt von Emster, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. The Option will vest in equal annual installments over three years, commencing on December 7, 2022, subject to the Mr. von Emster's continued service with the Issuer through each vesting date. Under an agreement between Mr. von Emster and the Reporting Person, Mr. von Emster is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of the Reporting Person. F3 · ownership.nature: ABV VII may be deemed the indirect beneficial owner of the Option, and Mr. von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Mr. von Emster, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
January 31, 2022 Filed Feb 1, 2022 17:00 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock, $0.001 par value	150,000	$27.00	$4,050,000.00	Disclosure SEC source: 0000905718-22-000177 · sierraonco_fm4jan282022.xml · nonDerivative · entry 2 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,314,127 F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
January 28, 2022 Filed Feb 1, 2022 17:00 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherSeries B Warrants (right to buy) · Derivative	287,471	$0.00 Strike: $13.20	$0.00	Disclosure SEC source: 0000905718-22-000177 · sierraonco_fm4jan282022.xml · derivative · entry 3 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 287,471 shares Expires not disclosed F2 · derivative.expiration_date: Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib. F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
January 28, 2022 Filed Feb 1, 2022 17:00 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock, $0.001 par value	287,471	$13.20	$3,794,617.20	Disclosure SEC source: 0000905718-22-000177 · sierraonco_fm4jan282022.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,164,127 F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 06, 2021 Filed Dec 17, 2021 21:30 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $11.36	$0.00	Disclosure SEC source: 0000905718-21-001618 · effector_fm4oct62021.xml · derivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-10-05 F2 · derivative.exercise_date: The option (the "Option") was granted to Brian Gallagher ("Gallagher"), a director of the Issuer and a member of the investment committee of ABV VI (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VI. The Option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Gallagher's continued service with the Issuer through each vesting date. Under an agreement between Gallagher and the Reporting Person, Gallagher is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of the Reporting Person. F1 · ownership.nature: Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VI, LP ("ABV VI"). Abingworth General Partner VI LLP serves as the general partner of Abingworth GP. ABV VI (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VI. F2 · ownership.nature: The option (the "Option") was granted to Brian Gallagher ("Gallagher"), a director of the Issuer and a member of the investment committee of ABV VI (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VI. The Option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Gallagher's continued service with the Issuer through each vesting date. Under an agreement between Gallagher and the Reporting Person, Gallagher is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of the Reporting Person. F3 · ownership.nature: ABV VI may be deemed the indirect beneficial owner of the Option, and Gallagher may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. Each of ABV VI, Abingworth GP, Abingworth General Partner VI LLP, Gallagher, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 01, 2021 Filed Mar 31, 2022 21:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock Option (right to buy) · Derivative	31,862	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0000905718-22-000523 · solenoth_fm4dec212018.xml · derivative · entry 6 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 31,862 Underlying: Common Stock · 31,862 shares Expires 2031-06-01 F10 · derivative.exercise_date: The option vests on the earlier of the twelve (12) month anniversary of June 1, 2021 or the day before the Issuer's next annual stockholder meeting, subject to Dr. Sinclair continuing to be a Service Provider through the vesting date. F1 · ownership.nature: Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII. F4 · ownership.nature: The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person. F5 · ownership.nature: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
May 18, 2021 Filed May 18, 2021 22:00 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	772,727	$11.00	$8,499,997.00	Disclosure SEC source: 0000905718-21-000712 · vera_fm4may132021.xml · nonDerivative · entry 2 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,960,231 F2 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Abingworth LLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
May 18, 2021 Filed May 18, 2021 22:00 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	ConversionClass A Common Stock	2,187,504	Not disclosed	Not disclosed	Disclosure SEC source: 0000905718-21-000712 · vera_fm4may132021.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,187,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F2 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Abingworth LLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
May 13, 2021 Filed May 18, 2021 22:00 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantStock Option (right to buy) · Derivative	9,925	$0.00 Strike: $11.00	$0.00	Disclosure SEC source: 0000905718-21-000712 · vera_fm4may132021.xml · derivative · entry 3 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 9,925 Underlying: Class A Common Stock · 9,925 shares Expires 2031-05-12 F3 · derivative.exercise_date: The options (the "Options") will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. The Options were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP. Abingworth LLP provides advisory services to ABV 8. Under an agreement between Von Emster and Abingworth LLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV 8, and must exercise the Option solely upon the direction of Abingworth LLP. F3 · ownership.nature: The options (the "Options") will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. The Options were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP. Abingworth LLP provides advisory services to ABV 8. Under an agreement between Von Emster and Abingworth LLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV 8, and must exercise the Option solely upon the direction of Abingworth LLP. F4 · ownership.nature: ABV 8 may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV 8. Abingworth LLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
January 08, 2021 Filed Mar 31, 2022 21:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $2.24	$0.00	Disclosure SEC source: 0000905718-22-000523 · solenoth_fm4dec212018.xml · derivative · entry 5 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-01-08 F9 · derivative.exercise_date: The option fully vested on January 8, 2021. F1 · ownership.nature: Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII. F4 · ownership.nature: The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person. F5 · ownership.nature: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 20, 2020 Filed Oct 21, 2020 20:05 UTC	Personalis, Inc. PSNL · Entity 4572	SaleCommon Stock, $0.0001 par value per share	130,486	$27.66	$3,609,242.76	Disclosure SEC source: 0000905718-20-001059 · personalis_fm4oct202020.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,753,340 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $29.07 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 19, 2020 Filed Oct 20, 2020 20:06 UTC	Personalis, Inc. PSNL · Entity 4572	SaleCommon Stock, $0.0001 par value per share	196,423	$27.86	$5,472,344.78	Disclosure SEC source: 0000905718-20-001057 · personalis_fm4oct162020.xml · nonDerivative · entry 2 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,883,826 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $28.80 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 16, 2020 Filed Oct 20, 2020 20:06 UTC	Personalis, Inc. PSNL · Entity 4572	SaleCommon Stock, $0.0001 par value per share	94,218	$26.68	$2,513,736.24	Disclosure SEC source: 0000905718-20-001057 · personalis_fm4oct162020.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,080,249 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $27.27 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 15, 2020 Filed Oct 16, 2020 20:05 UTC	Personalis, Inc. PSNL · Entity 4572	SaleCommon Stock, $0.0001 par value per share	3,700	$26.32	$97,384.00	Disclosure SEC source: 0000905718-20-001051 · personalis_fm4oct142020.xml · nonDerivative · entry 2 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,174,467 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $26.37 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 14, 2020 Filed Oct 16, 2020 20:05 UTC	Personalis, Inc. PSNL · Entity 4572	SaleCommon Stock, $0.0001 par value per share	81,925	$27.08	$2,218,529.00	Disclosure SEC source: 0000905718-20-001051 · personalis_fm4oct142020.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,178,167 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $29.07 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:05 UTC	Personalis, Inc. PSNL · Entity 4572	SaleCommon Stock, $0.0001 par value per share	86,819	$28.43	$2,468,264.17	Disclosure SEC source: 0000905718-20-001041 · personalis_fm4oct122020a.xml · nonDerivative · entry 2 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,260,092 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.42 to $29.19 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 12, 2020 Filed Oct 14, 2020 20:05 UTC	Personalis, Inc. PSNL · Entity 4572	SaleCommon Stock, $0.0001 par value per share	115,541	$29.09	$3,361,087.69	Disclosure SEC source: 0000905718-20-001041 · personalis_fm4oct122020a.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,346,911 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $30.72 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
August 18, 2020 Filed Aug 20, 2020 20:00 UTC	Personalis, Inc. PSNL · Entity 4572	SaleCommon Stock, $0.0001 par value per share	986,842	$19.00	$18,749,998.00	Disclosure SEC source: 0000905718-20-000875 · ownership.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,462,452 F1 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 26, 2020 Filed Jul 6, 2020 20:02 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseCommon Stock	3,333,330	$1.65	$5,499,994.50	Disclosure SEC source: 0000905718-20-000722 · ownership.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,302,602 F1 · ownership.nature: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on June 26, 2020. The shares are held by Abingworth Bioventures VII, LP ("Abingworth VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. F2 · ownership.nature: This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 11, 2020 Filed Jun 15, 2020 20:41 UTC	Vaxcyte, Inc. PCVX · Entity 1164	GrantStock option (right to buy) · Derivative	40,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000905718-20-000582 · vaxcyte_fm4jun1120.xml · derivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 40,000 Underlying: Common Stock, $0.001 par value per share · 40,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. F2 · ownership.direct: These options (the "Option") were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP. F3 · ownership.direct: ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: These options (the "Option") were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP. F3 · ownership.nature: ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 11, 2020 Filed Jun 16, 2020 22:26 UTC Amendment	Vaxcyte, Inc. PCVX · Entity 1164	GrantStock option (right to buy) · Derivative	40,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000905718-20-000584 · vaxcyte_fm4ajun1520.xml · derivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 40,000 Underlying: Common Stock, $0.001 par value per share · 40,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. F2 · ownership.direct: These options (the "Option") were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP. F3 · ownership.direct: ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: These options (the "Option") were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Von Emster and ALLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP. F3 · ownership.nature: ABV VI may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
May 18, 2020 Filed Mar 31, 2022 21:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock Option (right to buy) · Derivative	9,530	$0.00 Strike: $3.41	$0.00	Disclosure SEC source: 0000905718-22-000523 · solenoth_fm4dec212018.xml · derivative · entry 4 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 9,530 Underlying: Common Stock · 9,530 shares Expires 2030-05-18 F8 · derivative.exercise_date: The option fully vested on May 18, 2021. F1 · ownership.nature: Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII. F4 · ownership.nature: The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person. F5 · ownership.nature: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 12, 2019 Filed Nov 14, 2019 21:12 UTC	Protara Therapeutics, Inc. PRTO · Entity 6203	ConversionSeries A Convertible Preferred Stock · Derivative	126	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0000905718-19-000932 · proteonther_fm4nov122019.xml · derivative · entry 2 Abingworth LLP · CIK 0001397144 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,400 Underlying: Common Stock, $0.001 par value · 126,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A convertible preferred stock (the "Series A Stock") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. F3 · derivative.expiration_date: The Series A Stock has no expiration date. F4 · derivative.underlying_shares: The Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding. F1 · ownership.nature: The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
November 12, 2019 Filed Nov 14, 2019 21:12 UTC	Protara Therapeutics, Inc. PRTO · Entity 6203	ConversionCommon Stock, $0.001 par value	126,645	$0.99	$125,999.11	Disclosure SEC source: 0000905718-19-000932 · proteonther_fm4nov122019.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,144,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
October 25, 2019 Filed Oct 29, 2019 20:01 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	PurchaseCommon Stock	2,300,000	$1.20	$2,760,000.00	Disclosure SEC source: 0000905718-19-000873 · soleno_fm4oct252019.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,969,272 F1 · ownership.nature: The shares are held by Abingworth Bioventures VII, LP ("Abingworth VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 24, 2019 Filed Jun 26, 2019 10:53 UTC	Personalis, Inc. PSNL · Entity 4572	ConversionSeries C Preferred Stock · Derivative	878,361	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000905718-19-000553 · personalis_fm4jun242019.xml · derivative · entry 6 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $0.0001 par value per share · 878,361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. F2 · derivative.expiration_date: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. F2 · ownership.nature: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. Read SEC document
June 24, 2019 Filed Jun 26, 2019 10:53 UTC	Personalis, Inc. PSNL · Entity 4572	ConversionSeries B Preferred Stock · Derivative	2,065,217	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000905718-19-000553 · personalis_fm4jun242019.xml · derivative · entry 5 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $0.0001 par value per share · 2,065,217 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. F2 · derivative.expiration_date: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. F2 · ownership.nature: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. Read SEC document
June 24, 2019 Filed Jun 26, 2019 10:53 UTC	Personalis, Inc. PSNL · Entity 4572	ConversionSeries A Preferred Stock · Derivative	2,317,073	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000905718-19-000553 · personalis_fm4jun242019.xml · derivative · entry 4 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $0.0001 par value per share · 2,317,073 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. F2 · derivative.expiration_date: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. F2 · ownership.nature: Each share of Series A, Series B and Series C Preferred Stock is immediately convertible, at the option of the shareholder, into one share of Common Stock, $0.0001 par value per share ("Common Stock") and shall automatically convert into Common Stock upon the occurrence of certain events. Please see the Personalis, Inc. Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-231703) for a description of the conversion rights. Read SEC document
June 24, 2019 Filed Jun 26, 2019 10:53 UTC	Personalis, Inc. PSNL · Entity 4572	ConversionCommon Stock, $0.0001 par value per share	878,361	$0.00	$0.00	Disclosure SEC source: 0000905718-19-000553 · personalis_fm4jun242019.xml · nonDerivative · entry 3 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,449,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 24, 2019 Filed Jun 26, 2019 10:53 UTC	Personalis, Inc. PSNL · Entity 4572	ConversionCommon Stock, $0.0001 par value per share	2,065,217	$0.00	$0.00	Disclosure SEC source: 0000905718-19-000553 · personalis_fm4jun242019.xml · nonDerivative · entry 2 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,570,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 24, 2019 Filed Jun 26, 2019 10:53 UTC	Personalis, Inc. PSNL · Entity 4572	ConversionCommon Stock, $0.0001 par value per share	2,317,073	$0.00	$0.00	Disclosure SEC source: 0000905718-19-000553 · personalis_fm4jun242019.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,505,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 10, 2019 Filed Mar 31, 2022 21:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock Option (right to buy) · Derivative	13,000	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0000905718-22-000523 · solenoth_fm4dec212018.xml · derivative · entry 3 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-10 F7 · derivative.exercise_date: The option fully vested on May 17, 2020. F1 · ownership.nature: Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII. F4 · ownership.nature: The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person. F5 · ownership.nature: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
December 21, 2018 Filed Mar 31, 2022 21:31 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $1.57	$0.00	Disclosure SEC source: 0000905718-22-000523 · solenoth_fm4dec212018.xml · derivative · entry 2 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-12-21 F6 · derivative.exercise_date: The option vests in forty-eight (48) monthly installments commencing on December 21, 2018. F1 · ownership.nature: Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII. F4 · ownership.nature: The option was granted to Dr. Sinclair, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. Under an agreement between Dr. Sinclair and the Reporting Person, Dr. Sinclair is deemed to hold the option and any shares of common stock issuable upon exercise of the option, for the benefit of ABV VII, and must exercise the option solely upon the direction of the Reporting Person. F5 · ownership.nature: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Dr. Sinclair, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 08, 2018 Filed Jun 11, 2018 20:30 UTC	Protara Therapeutics, Inc. PRTO · Entity 6203	GrantStock Option (Right to Buy) · Derivative	12,700	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001171843-18-004576 · formfour.xml · derivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By affiliate Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2028-06-07 F2 · derivative.exercise_date: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders. F1 · ownership.direct: These options (the "Options") were granted to Tim Haines ("Haines"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Haines and ALLP, Haines is deemed to hold the Options and any shares of common stock issuable upon exercise of the Options for the benefit of ABV VI, and must exercise the Options solely upon the direction of ALLP. F3 · ownership.direct: ABV VI may be deemed the indirect beneficial owner of the Options, and Haines may be deemed the indirect beneficial owner of the Options through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Options except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Haines or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F1 · ownership.nature: These options (the "Options") were granted to Tim Haines ("Haines"), a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between Haines and ALLP, Haines is deemed to hold the Options and any shares of common stock issuable upon exercise of the Options for the benefit of ABV VI, and must exercise the Options solely upon the direction of ALLP. F3 · ownership.nature: ABV VI may be deemed the indirect beneficial owner of the Options, and Haines may be deemed the indirect beneficial owner of the Options through his indirect interest in ABV VI. ALLP disclaims beneficial ownership of the Options except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that ALLP, ABV VI, Haines or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
May 07, 2018 Filed May 9, 2018 21:10 UTC	Sientra, Inc. SIEN · Entity 108294	PurchaseCommon Stock	281,482	$13.50	$3,800,007.00	Disclosure SEC source: 0000905718-18-000472 · sientra_fm4may72018.xml · nonDerivative · entry 1 Abingworth LLP · CIK 0001397144 · Former 10% Holder 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes Disclosed balance after: 2,480,494 F1 · ownership.nature: Consists of (i) 1,240,247 shares held of record by Abingworth Bioventures V LP ("ABV V"), and (ii) 1,240,247 shares held of record by Abingworth Bioventures V Co-Invest Growth Equity Fund LP ("AGE"). ABV V and AGE are collectively referred to as the "Abingworth Funds." The investment manager of the Abingworth Funds is Abingworth LLP ("Abingworth"). Abingworth Bioventures V GP LP ("Abingworth GP"), a Scottish limited partnership, serves as the general partner of each of the Abingworth Funds. Abingworth General Partner V LLP, a Scottish limited liability partnership, serves as the general partner of Abingworth GP. Abingworth GP (acting by its general partner Abingworth General Partner V LLP) has delegated to Abingworth all investment and dispositive power over the shares held by the Abingworth Funds. The reporting person holds the reported securities indirectly through the Abingworth Funds. F2 · ownership.nature: The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, the Abingworth Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document
June 22, 2017 Filed Jun 26, 2017 20:26 UTC	Protara Therapeutics, Inc. PRTO · Entity 6203	PurchaseSeries A Convertible Preferred Stock · Derivative	2,526	$1,000.00 Strike: $0.99	$2,526,000.00	Disclosure SEC source: 0000905718-17-000622 · abingworth_fm4jun222017.xml · derivative · entry 1 Abingworth LLP · CIK 0001397144 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,526 Underlying: Common Stock, $0.001 par value · 2,538,949 shares Expires not disclosed F1 · derivative.exercise_price: The Series A convertible preferred stock (the "Series A Stock") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. F2 · derivative.expiration_date: The Series A Stock has no expiration date. F3 · derivative.underlying_shares: The Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding. F4 · ownership.nature: The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person holds the reported securities indirectly through Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.